PHARMAMEDICAL LTD


Directors	AKBARIAN TEFAGHI, Niloufar
	SALEHI, Parham


Registered Address	186 South Ealing Road
	London
	W5 4RJ


Registered Number	10867416 (England and Wales)

Balance Sheet as at
31 July 2025

	Notes	2025		2024
		£	£	£	£
Fixed assets
Intangible assets	3		148,450		200,950
Tangible assets	4		120,597		85,527
			269,047		286,477
Current assets
Stocks	5	25,150		26,475
Debtors	6	446,622		382,591
Cash at bank and on hand		217,254		171,386
		689,026		580,452
Creditors amounts falling due within one year	7	(465,486)		(480,532)
Net current assets (liabilities)			223,540		99,920
Total assets less current liabilities			492,587		386,397
Creditors amounts falling due after one year	8		(243,058)		(225,171)
Net assets			249,529		161,226
Capital and reserves
Called up share capital			100		100
Profit and loss account			249,429		161,126
Shareholders' funds			249,529		161,226

The company was entitled to exemption from audit for this reporting period under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company’s profit and loss account under section 444 (5A) Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 27 April 2026, and are signed on its behalf by:

SALEHI, Parham
Director
Registered Company No. 10867416

PHARMAMEDICAL LTD

Notes to the Financial Statements
for the year ended 31 July 2025

1.	Accounting policies

	Statutory information
	The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

	Statement of compliance
	The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.

	Turnover policy
	Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.

	Revenue from sale of goods
	Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

Revenue from sale of goods

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

	Employee benefits
	Contributions to defined contribution plans are expensed in the period to which they relate.

	Foreign currency translation
	Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

Foreign currency translation

Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

	Intangible assets
	Goodwill, being the amount paid in connection with the acquisition of a business in 2018, is being amortised evenly over its estimated useful life of ten years.

	Tangible fixed assets and depreciation
	Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:


		Reducing balance (%)
	Land and buildings	25
	Fixtures and fittings	25
	Vehicles	25
	Office Equipment	25

	Investments
	Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.

Investments

Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.

	Finance leases and hire purchase contracts
	Assets held under finance leases which are leases where substantially all the risks and rewards of ownership of the asset have passed to the company, and hire purchase contracts are capitalised in the balance sheet. They are depreciated over the shorter of their useful lives or the term of the lease.

	Stocks and work in progress
	Inventories are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).

2.	Average number of employees


		2025		2024
	Average number of employees during the year	13		13

3.	Intangible assets

	Goodwill	Total
	£	£
Cost or valuation
At 01 August 24	525,000	525,000
At 31 July 25	525,000	525,000
Amortisation and impairment
At 01 August 24	324,050	324,050
Charge for year	52,500	52,500
At 31 July 25	376,550	376,550
Net book value
At 31 July 25	148,450	148,450
At 31 July 24	200,950	200,950

4.	Tangible fixed assets

	Land & buildings	Vehicles	Fixtures & fittings	Office Equipment	Total
	£	£	£	£	£
Cost or valuation
At 01 August 24	85,694	61,652	10,531	73,678	231,555
Additions	-	56,690	-	1,915	58,605
At 31 July 25	85,694	118,342	10,531	75,593	290,160
Depreciation and impairment
At 01 August 24	60,969	25,759	4,795	54,505	146,028
Charge for year	6,181	11,127	1,434	4,793	23,535
At 31 July 25	67,150	36,886	6,229	59,298	169,563
Net book value
At 31 July 25	18,544	81,456	4,302	16,295	120,597
At 31 July 24	24,725	35,893	5,736	19,173	85,527

5.	Stocks

	2025	2024
	£	£
Finished goods	25,150	26,475
Total	25,150	26,475

6.	Debtors: amounts due within one year

	2025	2024
	£	£
Trade debtors / trade receivables	243,975	242,934
Amounts owed by group undertakings	64,558	49,250
Other debtors	132,199	84,592
Prepayments and accrued income	5,890	5,815
Total	446,622	382,591

7.	Creditors: amounts due within one year

	2025	2024
	£	£
Trade creditors / trade payables	216,442	219,896
Bank borrowings and overdrafts	44,116	44,116
Taxation and social security	70,414	67,708
Payments received on account	91,943	116,774
Finance lease and HP contracts	10,338	-
Other creditors	31,836	31,641
Accrued liabilities and deferred income	397	397
Total	465,486	480,532


	Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

8.	Creditors: amounts due after one year

	2025	2024
	£	£
Bank borrowings and overdrafts	243,058	225,171
Total	243,058	225,171

9.	Related party transactions
	At the year end, Betapharma Ltd owed £64,558 (2024: 49,250) to the company. The companies are related as Mr. Parham Salehi is also the director of this company.